Kabalin J N
Department of Urology, Stanford University School of Medicine, CA.
Geriatrics. 1992 Sep;47(9):26-32.
Prostate specific antigen (PSA) has replaced prostatic acid phosphatase as the preeminent clinical tumor marker in the management of patients with prostate cancer. Serum PSA levels have been shown to be proportional to clinical and pathologic stage of prostate cancer and in particular to correlate closely with prostate cancer volume. Serum levels of PSA thus serve as a useful adjunct in the initial clinical staging of men with prostate cancer. Serum PSA values provide a unique and valuable tool in monitoring prostate cancer progression over time and its response to surgical, radiation, and/or hormonal therapies. Unfortunately, its lack of specificity for prostate cancer leaves many questions unanswered as to the efficacy and advisability of using PSA as a screening test for this cancer.
前列腺特异性抗原（PSA）已取代前列腺酸性磷酸酶，成为前列腺癌患者管理中最重要的临床肿瘤标志物。血清PSA水平已被证明与前列腺癌的临床和病理分期成正比，尤其与前列腺癌体积密切相关。因此，血清PSA水平可作为前列腺癌男性患者初始临床分期的有用辅助手段。血清PSA值为监测前列腺癌随时间的进展及其对手术、放疗和/或激素治疗的反应提供了一个独特且有价值的工具。不幸的是，其对前列腺癌缺乏特异性，使得关于将PSA用作该癌症筛查试验的有效性和可取性存在许多未解答的问题。
